Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.31 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.31 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.31 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.31 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.31 |
| ▸ | ATP1B3 | P54709 | 1/20 | 0.31 |
| ▸ | FXYD2 | P54710 | 1/20 | 0.31 |
| ▸ | ATP1A4 | Q13733 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17600236 | 0.84 | — | — | |
| SCHEMBL17600126 | 0.76 | — | — | |
| SCHEMBL2041614 | 0.76 | ALDH1A1 (0.33) | — | |
| SCHEMBL17600044 | 0.72 | — | — | |
| SCHEMBL17600051 | 0.71 | TSHR (0.37) | — | |
| SCHEMBL17600086 | 0.69 | — | — | |
| SCHEMBL17600146 | 0.69 | ABL1 (0.39) | — | |
| SCHEMBL16911448 | 0.66 | — | — | |
| SCHEMBL17600143 | 0.66 | — | — | |
| SCHEMBL17600258 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3006440-B1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL CO (JP) | 2018-03-21 | — | — | EP | disclosed |
| US-9675072-B2 | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-06-13 | — | — | US | disclosed |
| EP-3006440-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | Sumitomo Chemical Company Limited (JP) | 2016-04-13 | — | — | EP | disclosed |
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-03-24 | — | — | US | disclosed |
| CN-105263921-A | Tetrazolinone compound and application of same | SUMITOMO CHEMICAL CO | 2016-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160081340-A1 | TETRAZOLINONE COMPOUND AND APPLICATION OF SAME | CYP2E1, MT-CO2, CASP3 | HTR2A 3577/4885HTR2C 1713/4885HTR2B 3091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.